Hepatic steatosis in inflammatory bowel disease: practical questions and evidence-based answers

Abstract

Hepatic steatosis is among the most frequent hepatobiliary abnormalities in inflammatory bowel disease (IBD), but its clinical interpretation is increasingly complex. This narrative review provides evidence-based guidance for gastroenterologists managing adults with IBD and hepatic steatosis. Cohort and meta-analytic evidence indicates that hepatic steatosis affects approximately one-quarter to one-third of patients with IBD, although estimates vary according to diagnostic method, population selection, disease phenotype, metabolic burden, and study design. Metabolic dysfunction-associated steatotic liver disease (MASLD) provides a useful framework for patients with cardiometabolic dysfunction, but a steatosis-centered approach is more inclusive in IBD because it accommodates lean or undernourished patients, inflammation-associated phenotypes, ileal or bile acid-related mechanisms, alcohol overlap, medication-related vulnerability, and mixed presentations. The main clinical priority is not merely to detect liver fat, but to identify meaningful fibrosis, cardiometabolic risk, and modifiable contributors. Normal aminotransferases do not exclude steatosis or fibrosis. Screening should be risk-based rather than universal. Fibrosis-4 index can be used pragmatically for initial triage in stable adults, but its IBD-specific limitations require cautious interpretation; transient elastography is most useful as a secondary fibrosis assessment or as a combined first test when readily available. Follow-up should be driven by fibrosis and cardiometabolic risk rather than by IBD alone, and hepatology referral should be reserved for elevated liver stiffness, persistent or cholestatic liver-test abnormalities, portal-hypertension features, suspected alternative liver disease, discordant tests, or clinically significant hepatic dysfunction. Hepatic steatosis alone should not determine IBD drug selection, although liver dysfunction and treatment-specific hepatotoxicity may modify monitoring or therapeutic choices.